<DOC>
	<DOCNO>NCT00035633</DOCNO>
	<brief_summary>The purpose clinical research study assess safety effectiveness entecavir , compare lamivudine , treatment adult chronic hepatitis B infection hepatitis B e antigen positive .</brief_summary>
	<brief_title>A Phase III Study Entecavir v Lamivudine Adults With Chronic Hepatitis B Infection Positive Hepatitis B E Antigen</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male female subject =/ &gt; 16 year age ( minimum age require give country ) history chronic hepatitis B infection ; Documentation positive Hepatitis B e antigen ( HBeAg ) status . ; The absence coinfection immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) hepatitis D virus ( HDV ) ; The absence form liver disease e.g. , alcoholic , autoimmune , biliary disease ; Less 12 week prior therapy nucleoside nucleotide analogue antiviral agent activity hepatitis B ( e.g. , adefovir , famciclovir lamivudine )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>